a 501(c)(3) educational nonprofit organization

A N N U A L R E P O R T

The 2014 Meeting Season (October 2013 – June 2014)

Advancing Vaccines in the Genomics Era (T1) Oct 31–Nov 4, 2013 | Windsor Barra Hotel | Rio de Janeiro | Brazil

Sensing and Signaling of Hypoxia: Interfaces with Biology and Medicine (A1) Jan 7–12, 2014 | Beaver Run Resort | Breckenridge, Colorado | USA

The Ubiquitin System: From Basic Science to Drug Discovery (A2) Jan 7–12, 2014 | Big Sky Resort | Big Sky, Montana | USA

Nuclear Receptors: Biological Networks, Genome Dynamics and Disease (A3) Jan 10–15, 2014 | Sagebrush Inn and Conference Center | Taos, New Mexico | USA

Tissue-Resident Memory T Cells (A4) Jan 12–16, 2014 | Snowbird Resort | Snowbird, Utah | USA

Aging – Pushing the Limits of Cellular Quality Control (A5) Jan 12–17, 2014 | Sheraton Steamboat Resort | Steamboat Springs, Colorado | USA

Challenges and Opportunities in Diabetes Research and Treatment (J1) joint with Obesity: A Multisystems Perspective (J2) Jan 12–17, 2014 | Fairmont Hotel Vancouver | Vancouver, British Columbia | Canada

Emerging Cytokine Networks (J3) joint with Inflammatory Diseases: Recent Advances in Basic and Translational Research and Therapeutic Treatments (J4) Jan 17–22, 2014 | Fairmont Hotel Vancouver | Vancouver, British Columbia | Canada

Pathogenesis of Respiratory Viruses (J5) joint with Innate Immunity to Viral Infections (J6) Jan 19–24, 2014 | Keystone Resort | Keystone, Colorado | USA

New Frontiers in the Discovery and Treatment of Thrombosis (A6) Jan 26–30, 2014 | Keystone Resort | Keystone, Colorado | USA

Mechanisms and Consequences of Invertebrate-Microbe Interactions (A7) Jan 26–30, 2014 | Granlibakken Resort | Tahoe City, California | USA

Growth and Wasting in Heart and Skeletal Muscle (A8) Jan 26–31, 2014 | Eldorado Hotel & Spa | Santa Fe, New Mexico | USA

RNA Silencing (A9) Jan 31–Feb 5, 2014 | Sheraton Seattle Hotel | Seattle, Washington | USA

The Science of Malaria Eradication (F1) Feb 2–7, 2014 | Fiesta Americana | Merida, Yucatan | Mexico

Developmental Pathways and Cancer: Wnt, Notch and Hedgehog (J7) joint with Stem Cells and Cancer (J8) Feb 2–7, 2014 | Fairmont Banff Springs | Banff, Alberta | Canada

Cancer Epigenetics (Q1) joint with Transcriptional Regulation (Q2) Feb 4–9, 2014 | Santa Fe Community Convention Center | Santa Fe, New Mexico | USA

Plant Signaling: Dynamic Properties (B1) Feb 5–10, 2014 | Beaver Run Resort | Breckenridge, Colorado | USA

Molecular Cell Biology of Macrophages in Human Diseases (B2) Feb 9–14, 2014 | Hilton Santa Fe Historic Plaza Hotel | Santa Fe, New Mexico | USA

Prophylactic and Therapeutic Antibodies (Q3) joint with Biology of B Cell Responses (Q4) Feb 9–14, 2014 | Keystone Resort | Keystone, Colorado | USA

Omics Meets Cell Biology: Applications to Human Health and Disease (B3) Feb 18–23, 2014 | Sagebrush Inn and Conference Center | Taos, New Mexico | USA

Mitochondrial Dynamics and Physiology (Q5) joint with The Chemistry and Biology of Cell Death (Q6) Feb 18–23, 2014 | Santa Fe Community Convention Center | Santa Fe, New Mexico | USA

The NF-κB System in Health and Disease (B4) Feb 23–28, 2014 | Keystone Resort | Keystone, Colorado | USA

Long Noncoding RNAs: Marching toward Mechanism (B5) Feb 27–Mar 4, 2014 | Eldorado Hotel & Spa | Santa Fe, New Mexico | USA

Cilia, Development and Human Disease (C1) Mar 2–7, 2014 | Granlibakken Resort | Tahoe City, California | USA

Parkinson’s Disease: Genetics, Mechanisms and Therapeutics (Q7) joint with Alzheimer’s Disease – From Fundamental Insights to Light at the End of the Translational Tunnel (Q8) Mar 2–7, 2014 | Keystone Resort | Keystone, Colorado | USA

Mobile Genetic Elements and Genome Evolution (C2) Mar 9–14, 2014 | Hilton Santa Fe Historic Plaza Hotel | Santa Fe, New Mexico | USA

Inflammation, Infection and Cancer (X1) joint with Immune Evolution in Cancer (X2) Mar 9–14, 2014 | Fairmont Chateau Whistler | Whistler, British Columbia | Canada

HIV Vaccines: Adaptive Immunity and Beyond (X3) joint with HIV Pathogenesis–Virus vs. Host (X4) Mar 9–14, 2014 | Fairmont Banff Springs | Banff, Alberta | Canada

Metabolism and Angiogenesis (X5) joint with Tumor Metabolism (X6) Mar 16–21, 2014 | Whistler Conference Centre | Whistler, British Columbia | Canada

Lipid Pathways in Biology and Disease (C3) Mar 19–24, 2014 | Royal Dublin Society | Dublin | Ireland

Big Data in Biology (F2) Mar 23–25, 2014 | Fairmont San Francisco | San Francisco, California | USA

Fibrosis: From Bench to Bedside (C4) Mar 23–28, 2014 | Keystone Resort | Keystone, Colorado | USA

Chromatin Mechanisms and Cell Physiology (C5) Mar 23–28, 2014 | Oberstdorf Haus | Oberstdorf | Germany

Complications of Diabetes (X7) joint with Innate Immunity, Metabolism and Vascular Injury (X8) Mar 23–28, 2014 | Whistler Conference Centre | Whistler, British Columbia | Canada

The Ins and Outs of Viral Infection: Entry, Assembly, Exit and Spread (C6) Mar 30–Apr 4, 2014 | Beaver Run Resort | Breckenridge, Colorado | USA

Novel Therapeutic Approaches to Tuberculosis (C7) Mar 30–Apr 4, 2014 | Keystone Resort | Keystone, Colorado | USA

G Protein-Coupled Receptors: Structural Dynamics and Functional Implications (Z1) joint with Frontiers of Structural Biology (Z2) Mar 30–Apr 4, 2014 | Snowbird Resort | Snowbird, Utah | USA

Exploiting and Understanding Chemical Biotransformations in the Human Microbiome (D1) Apr 1–6, 2014 | Big Sky Resort | Big Sky, Montana | USA

Epigenetic Programming and Inheritance (D2) Apr 6–10, 2014 | Boston Park Plaza | Boston, Massachusetts | USA

Emerging Concepts and Targets in Islet Biology (D3) Apr 6–11, 2014 | Keystone Resort | Keystone, Colorado | USA

Engineering Cell Fate and Function (Z3) joint with Stem Cells and Reprogramming (Z4) Apr 6–11, 2014 | Resort at Squaw Creek | Olympic Valley, California | USA

Adult Neurogenesis (E1) May 12–17, 2014 | Clarion Hotel Sign | Stockholm | Sweden

Autophagy: Fundamentals to Disease (E2) May 23–28, 2014 | Hyatt Regency Austin | Austin, Texas | USA

The Brain: Adaptation and Maladaptation in Chronic Pain (E3) Jun 15–20, 2014 | Keystone Resort | Keystone, Colorado | USA

background photo: Austin, Texas, new location for Keystone Symposia and site of the 2014 Autophagy conference

3

From the Chair of the Board

3

Reflecting growing optimism about the economy and funding for science, Keystone Symposia increased the number of meetings back to 58 in Fiscal Year 2014 from 52 the previous year. Although attendance was somewhat sluggish and did not yet rebound

to pre-recession levels, the meetings continued to be rated very highly for quality, as were the staff and venues. Strong funding support from corporate, government and individual sources allowed us to program a number of meetings on new topics or ones in the early stages of research – such as our second conference on “Cilia,” a conference on “Big Data in Biology” in a shortened two-day format, and our first conference on “Parkinson’s Disease” held jointly with one on Alzheimer’s. Without this generous external support, we would not be able to hold such important smaller meetings. I would like to thank all the corporate, foundation, individual and government donors who provide such vital support to make this possible. In April 2014, we welcomed Dr. Jane Peterson as the new President and Chief Executive Officer of Keystone Symposia, replacing Dr. James Aiken who served the organization for 11 years. Dr. Aiken graciously agreed to stay on for most of calendar year 2014 to ease the transition, and I would like to thank him again for his outstanding leadership of Keystone Symposia. Among other accomplishments, Dr. Aiken launched Keystone Symposia into the international arena with the first conferences held in Africa, Asia, Australia, Europe and South America all occurring during his tenure. He was also instrumental in establishing key partnerships with funding entities that include the Bill & Melinda Gates Foundation, Science Foundation Ireland, Science for Life Laboratory and the Knut and Alice Wallenberg Foundation, and Brazilian federal and regional government entities. Dr. Peterson comes to Keystone Symposia from the National Human Genome Research Institute (NHGRI) of the National Institutes of Health. At the NHGRI, she was instrumental in a number of overseas projects such as the Human Heredity and Health in Africa (H3Africa) initiative. This background is extremely valuable since a key ongoing objective for Keystone Symposia is a growing presence outside North America.

Fiscal year 2014 saw Keystone Symposia hold its first “virtual” event. This was a webcast panel discussion among four experts on “HIV/AIDS: Strategies for an Endgame” that was watched by viewers worldwide. While such online events cannot replace the priceless face-to-face interactions from actually attending a multi-day symposium, they will supplement the Keystone Symposia conference experience and allow us to bring the conversation to a broader worldwide audience.

Thank you again to all who organize, present at, attend and support Keystone Symposia meetings. Through your participation, you become part of a unique, collaborative discourse that can truly accelerate life science discovery.

Sincerely,

Juleen R. Zierath, Ph.D.Chair, Board of Directors, Keystone Symposia Professor, Karolinska Institutet

These are unprecedented and exciting times in cell and molecular biology, and I am thrilled to be joining an organization that is truly at the hub of the latest and most innovative work being done in the life sciences. Since being appointed Chief Executive

Officer in April 2014, I have focused on learning about the organization as well as looking toward its future. I owe a debt of gratitude to the outstanding Keystone Symposia staff and members of the Board of Directors who have actively helped me adjust to this role.

I spent most of my scientific career at the NIH in the National Human Genome Research Institute (NHGRI), where I worked on the Human Genome Project (HGP) and many of the genomic projects which followed from the HGP. While my personal interests lie in ‘omics of all types, I am looking forward to learning more about the many scientific areas encompassed by Keystone Symposia.

My interest in science extends to promoting international science. I worked on several international projects at NIH and strongly believe that today science is global in scope. I hope to enrich the scientific discourse at Keystone Symposia meetings by including more diverse voices in the conversation. To do so, I plan to expand the number of Keystone Symposia meetings held outside of North America. I also hope to expand the number of meetings held in low and middle income countries in Africa and South America; already in 2014-15 we will be holding two meetings in Brazil. My purpose in doing so is to broaden Keystone Symposia’s contribution to the development of scientific infrastructure and to promote the science that is flourishing on those continents.

We greatly value the financial support of corporations, foundations, governments and individuals. Since Keystone Symposia does not have an endowment, this continuing diverse base of support on an annual basis is vital. Through generous donations, we are able to defer some of the expenses of many deserving early-career scientists and also offset many of the costs we would otherwise have to pass on to attendees.

Thank you for your support of Keystone Symposia. I hope to meet many of you in the near future.

Sincerely,

Jane L. Peterson, Ph.D.President and Chief Executive Officer, Keystone Symposia

From the Chief Executive Officer

From left: organizers of Keystone Symposia’s June 2014 “Chronic Pain” conference present to the local community in Silverthorne, Colorado; attendees of Keystone Symposia’s “The Science of Malaria Eradication” conference in February 2014 scale a Mayan pyramid near Merida, Mexico; participants gather for a group photo at Keystone Symposia’s first conference in Oberstdorf, Germany (on “Chromatin Mechanisms and Cell Physiology” in March 2014).

Mission and Accomplishments

The Mission

Keystone Symposia will serve as a catalyst for the advancement of biomedical and life sciences by connecting scientists within and across disciplines at conferences and workshops held at venues that create an environment conducive to information exchange,

generation of new ideas and acceleration of applications that benefit society.

Notable Achievements and Milestones in Fiscal Year 2014

Fiscal Year 2014 featured 58 meetings across a diverse range of the life sciences that attracted the participation of 12,235 scientists from all over the world (83 countries). The majority of scientists were affiliated with academia (68%), with the remainder (32%) coming from industry, government and nonprofit/nongovernment organizations (6% of participants did

not disclose their affiliation). FY14 student and postdoc participation was 40% – slightly higher than the 2013 meeting season (39%). In keeping with trends from prior years, just over half of the attendees (51%) who disclosed year of birth were under 45 years of age. In general, attendee demographics were similar to those of the previous two years, with a slight up-tick in participation by industry (from 13% in FY13 to 15% in FY14).

• Keystone Symposia was able to award 443 scholarships for meeting attendance to deserving graduate students and postdoctoral fellows, funded by its own operating fund as well as generous donor support.

• Women were well-represented among scholarship recipients, and 69 of the recipients received scholarships specially designated for those from underrepresented backgrounds. The majority of those recipients were Hispanic American (43%) and African American (43%).

• Thanks to support from the Bill & Melinda Gates Foundation, 138 investigators and clinicians from developing countries received Global Health Travel Awards enabling them to attend infectious disease meetings in the 2014 Keystone Symposia Global Health Series.

• Keystone Symposia held its first conference in Mérida, Yucatán, Mexico (on “The Science of Malaria Eradication”). Additional new conference venues in FY14 included Rio de Janeiro, Brazil (“Advancing Vaccines in the Genomics Era”), San Francisco, California, USA (“Big Data in Biology”), Oberstdorf, Germany (“Chromatin Mechanisms and Cell Physiology”) and Austin, Texas, USA (“Autophagy: Fundamentals to Disease”).

• Exit survey respondents gave high ratings for professional development opportunities at the Keystone Symposia conferences regardless of career stage, affiliation or meeting role. 80% agreed that they made a useful contact at the conference they attended that will lead to a collaboration or sharing of information, data or techniques. Similarly, respondents recognized that the meeting had potential to impact their research regardless of career stage or affiliation. 87% of attendees agreed that the conference facilitated interactions between junior and senior investigators.

• Exit survey respondents reported very high ratings for the scientific content of the meetings regardless of age, region, affiliation or occupation, continuing the same trend observed over the last few years. 92% of participants rated the scientific content “Excellent” or “Very Good.”

• Keystone Symposia held its first online webcast event. 1,476 individuals registered to view this panel discussion on the topics of “HIV/AIDS: Strategies for an Endgame” either live when it aired on December 13, 2013 or in archived form. Visit www.keystonesymposia.org/vks to watch.

• Keystone Symposia conducted two events to share science with the lay public: one on “Breakthroughs in Alzheimer’s Research” on March 4, 2014 and another on “Chronic Pain, Migraine and the Brain” on June 17, 2014. Featuring leading scientists presenting at Keystone Symposia conferences on the same topic, each was attended by more than 100 members of the local Summit County, Colorado community and was also filmed for broadcast to a wider audience. Visit www.keystonesymposia.org/videos or Keystone Symposia’s YouTube channel at www.youtube.com/KeystoneSymposia to watch these in their entirety.

background photo: Yucatan pyramid in Merida, Mexico, new location for Keystone Symposia and site of the 2014 “The Science of Malaria Eradication” conference

2014 EXPENSE BREAKDOWN

The charts below are intended to provide a snapshot of Keystone Symposia’s 2014 finances and activities. Please visit keystonesymposia.org/AboutUs/AnnualReport.cfm to view the full audited statement of financial condition and statement of activities for the fiscal year July 1, 2013 – June 30, 2014.

2014 STATEMENT OF ACTIVITIES

Investment Income/Miscellaneous Income (17.37%)

Corporate & Foundation Gifts (15.59%)

Government Grants (4.84%)

Individual Gifts (.21%)

Registration Fees/Earned Income(61.99%)

4

Breakdown of the Year

Educational Programs (74.25%)

Fundraising & Development (4.44%)

Management & General (21.31%)

Temporarily Unrestricted Restricted Total

Revenues

Registration revenue and other $ 11,368,746 $ – $ 11,368,746 Contributions 1,015,997 1,462,007 2,478,004 Government grants 758,396 – 758,396 Net investment income 1,073,343 – 1,073,343 Released from restrictions 1,958,322 (1,958,322) – Total revenues 16,174,804 (496,315) 15,678,489 Expenses

Program expenses 10,740,800 – 10,740,800 Management & general expenses 3,082,902 – 3,082,902 Fundraising expenses 641,677 – 641,677 Total expenses 14,465,379 – 14,465,379 Change in Net Assets 1,709,425 (496,315) 1,213,110 Net Assets – Beginning of Year 9,776,177 3,355,680 13,131,857 Net Assets – End of Year $ 11,485,602 $ 2,859,365 $ 14,344,967

74.25% of Keystone Symposia’s expenditures in fiscal year 2014 went toward educational programs including meeting programs, scholarships, travel awards and diversity initiatives.

2014 REVENUE BREAKDOWN

Investment Income/Miscellaneous Income (17.37%)

2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014

13,956

7,340

13,509

6,587

13,015

5,962

11,512

5,736

11,222

5,400

Attendees & Speakers

Abstract Submissions*

2004 2005 2006 2007 2008 2009 2010 2011* 2012* 2013* 2014*

929903

711681

619

546Scholarships

Underrepresented Trainee Scholarships& Travel Awards

Global Health Travel Awards

TOTAL MEETING ATTENDANCE & ABSTRACT SUBMISSIONS*

SCHOLARSHIPS & TRAVEL AWARDS

12,303

6,547

930

5

AVERAGE ATTENDANCE & ABSTRACTS* PER MEETING

2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014

Average Attendance

Average Number of Abstracts*

585650544446 52

6,857

13,554

244262

241

270242 241 237

117 130110

132 122 127 126Number of Meetings

*abstract count does not include speaker abstracts

*abstract count does not include speaker abstracts

13,770

7,381

55

250

134

882*

*Scholarship amount was increased from $1,000 to $1,200 in 2011, which reduced the total number awarded.

12,360

7,031

55

225

120

835*

12,579

6,603

237

133

53

623*586*

12,235

6,587

211

114

58

Temporarily Unrestricted Restricted Total

Revenues

Registration revenue and other $ 11,368,746 $ – $ 11,368,746 Contributions 1,015,997 1,462,007 2,478,004 Government grants 758,396 – 758,396 Net investment income 1,073,343 – 1,073,343 Released from restrictions 1,958,322 (1,958,322) – Total revenues 16,174,804 (496,315) 15,678,489 Expenses

Program expenses 10,740,800 – 10,740,800 Management & general expenses 3,082,902 – 3,082,902 Fundraising expenses 641,677 – 641,677 Total expenses 14,465,379 – 14,465,379 Change in Net Assets 1,709,425 (496,315) 1,213,110 Net Assets – Beginning of Year 9,776,177 3,355,680 13,131,857 Net Assets – End of Year $ 11,485,602 $ 2,859,365 $ 14,344,967

MEETING “EXCELLENT” RATINGS AS A PERCENT OF ALL RATINGS (BASED ON ATTENDEE SURVEYS)

VALUE PARTICIPANTS GAINED FROM THE 2014 MEETINGS (BASED ON ATTENDEE SURVEYS)

Poster/Abstract Quality

Quality of Plenary Speakers

Overall Scientific Content Quality

60%

55%

50%

45%

40%

35%

30%

25%

20% 2007 2008 2009 2010 2011 2012 2013 2014

Made a Useful Contact Saved Research Time/Money or Meeting Facilitated Learned New Methodology Accelerated Research Objectives Junior-Senior Interactions (N=4,920) (N=4,920) (N=4,920) (N=4,920)

6

80%

16%

4%

33%

63%

4%

Agree

Neutral or N/A

Disagree

PARTICIPATION OF THE NEXT GENERATION OF INVESTIGATORS (PERCENT OF TOTAL & ABSOLUTE NUMBERS)

2008 2009 2010 2011 2012 2013 2014

64(4%)

109(7%)

92(7%)

130(9%)

Assistant Professor & Early-Stage Investigator Speakers & Organizers

Total Assistant Professor & Early-Stage Investigator Attendees

Total Student & Postdoctoral Fellow Attendees

1,143(8%)

1,104(9%)

1,403(10%)

5,415(39%)

4,930(40%)

5,564(41%)

941(7%)

5,368(40%)

160(11%)

1,222(10%)

4,679(38%)

4%9%

87%

4,863(39%)

1,388(11%)

111(7%)

74%

4%

22%

4,813(39%)

1,120(9%)

128(8%)

Keystone Symposia is fortunate to receive substantial ongoing support from the pharmaceutical and biotechnology industries, charitable foundations and individuals. We are also honored to be the recipient of numerous grants from the US National Institutes of Health and other government agencies around the world. These gifts and grants are used to provide

scholarships for graduate students and postdoctoral fellows, travel awards for scientists from developing nations and subsidies for the travel and lodging costs of scientific speakers from academic and other nonprofit laboratories and institutions.

For the 2014 meeting season and fiscal year, we received a total of $4.7 million from government, corporate, foundation and individual sources, as shown in the chart below. This funding is crucial in supporting Keystone Symposia’s mission to serve as a catalyst for the advancement of biomedical and life sciences and to accelerate applications that benefit humankind.

Keystone Symposia gratefully acknowledges donors who gave in the 2014 fiscal year. Their generous support makes possible the outstanding scientific quality of our meetings and unique opportunities for interaction and collaboration among participants. To make a gift, please contact the Development office by telephone at 970.262.2690 or by e-mail at development@keystonesymposia.org. “Future of Science Fund” individual donations can also be made over the Internet at www.keystonesymposia.org/ScienceFund. And please consider becoming a member of The Keystone Society – a way to remember Keystone Symposia in your estate planning.

Christopher Atwood, D.Min.Director of Development, Keystone Symposia

7

Poster/Abstract Quality

Quality of Plenary Speakers

Overall Scientific Content Quality

Assistant Professor & Early-Stage Investigator Speakers & Organizers

Total Assistant Professor & Early-Stage Investigator Attendees

Total Student & Postdoctoral Fellow Attendees

Donor Support

Corporate Gifts: $1,835,150 (39%)

Foundation Gifts: $1,058,039(23%)

US Federal Government Grants: $681,193(14%)

Other Government Grants: $147,203 (3%)

In-Kind Gifts:$853,855(18%)

Individual Gifts: $72,564 (2%)

Academic Journals: $50,000(1%)

CHAMPIONSTop-tier donors making an ongoing, annual commitment of $100,000+. Their public championing of Keystone Symposia’s cause provides inspirational leadership commitment to our shared scientific mission of catalyzing collaborations, accelerating discoveries, and preparing and positioning the next generation of leading life scientists.

Educational donation provided by Amgen*Bayer HealthCare Pharmaceuticals*Bill & Melinda Gates FoundationGenentech, Inc.*Merck & Co., Inc.*Minas Gerais State Agency for Research Development (FAPEMIG) – Brazil

SUSTAINING BENEFACTORSDonors making a three-year commitment of at least $50,000 per year. Their generous support is crucial to sustain Keystone Symposia’s ability to plan future scientific conferences focused on emerging topics and excellence in science.

AstraZeneca*Cell Research*

BENEFACTORSDonors of $50,000 or above. We are very grateful for their extraordinary commitment to our mission to connect the scientific community and accelerate discoveries that benefit society. Special thanks to those organizations that provide consistent, annual Benefactor-level support.

BioLegend, Inc.*California Institute for Regenerative Medicine (CIRM)Gilead Sciences, Inc.*

SUSTAINING SPONSORSDonors making a three-year commitment of $25,000 to $49,999 per year. Their generous support is crucial to Keystone Symposia’s ability to plan future scientific conferences focused on emerging topics and excellence in science.

AbbVie Inc.*Arena Pharmaceuticals, Inc.*Astellas Pharma Inc.*Biogen Idec*Boehringer Ingelheim Pharmaceuticals, Inc.*Celgene Corporation*Constellation Pharmaceuticals*Curemark LLC*H3 Biomedicine Inc.*Infinity Pharmaceuticals, Inc.*

SPONSORSDonors contributing $25,000 to $49,999. These generous gifts allow us to convene meetings in a wide variety of important areas. Special thanks to those organizations that provide consistent, annual Sponsor-level support.

Bristol-Myers Squibb Company*GlaxoSmithKline*InterMune, Inc.*Isis Pharmaceuticals, Inc.*

The listings on this page and the next five pages reflect donations for the fiscal year beginning July 1, 2013 and ending June 30, 2014.

8*Indicates a gift to the Directors’ Fund, which allows Keystone Symposia’s President/CEO and Directors to schedule and support meetings in the early stages of research.

Donor Support

Life Technologies Corporation* MedImmune* Nestlé Institute of Health Sciences* Novartis Institutes for BioMedical Research* OncoMed Pharmaceuticals, Inc.* Sangamo BioSciences, Inc.* Shire Human Genetic Therapies* TESARO, Inc.* Theravance, Inc.* Vertex Pharmaceuticals Incorporated*

Janssen R&D: Pharmaceutical Companies of Johnson & Johnson*Monsanto Company*Sanofi US*

National Council for Scientific and Technological Development (CNPq) – Brazil Novo Nordisk A/S*Pfizer Inc.*Roche*Science for Life Laboratory – StockholmKnut and Alice Wallenberg Foundation

Regeneron Pharmaceuticals, Inc.*Takeda Pharmaceutical Company Limited*

Educational grant from Lilly*MESA — Malaria Eradication Scientific AllianceScience Foundation Ireland

The listings on this page and the next five pages reflect donations for the fiscal year beginning July 1, 2013 and ending June 30, 2014.

9

PARTNERS, PATRONS, DONORS AND CONTRIBUTORS

Keystone Symposia wishes to thank the following donors to the 2014 meeting series. Their generous support makes possible the outstanding scientific quality of our meetings and unsurpassed opportunities for interaction among attending scientists.

PARTNERS($10,000–$24,999)

Cell Signaling Technology, Inc.Genzyme Corporation*Gordon and Betty Moore Foundation

DIRECTORS’ FUND CHAMPIONS & BENEFACTORSThe following donors with unrestricted gifts of $50,000 or more enabled Keystone Symposia’s President/CEO and Directors to schedule meetings in a variety of important areas, many of which are in the early stages of research.

AstraZeneca Educational donation provided by AmgenBayer HealthCare PharmaceuticalsBioLegend, Inc.Cell Research Genentech, Inc.Gilead Sciences, Inc.

DIRECTORS’ FUND SPONSORSThe following donors with unrestricted gifts from $25,000 to $49,999 also provided invaluable support to the Directors’ Fund.

AbbVie Inc.Educational donation provided by AmgenArena Pharmaceuticals, Inc.Astellas Pharma Inc.AstraZenecaBayer HealthCare PharmaceuticalsBiogen IdecBioLegend, Inc.Boehringer Ingelheim Pharmaceuticals, Inc.Bristol-Myers Squibb CompanyCelgene CorporationCell Research

PATRONS($5,000–$9,999)

Abcam plc*AdipoGen International*Alzheimer’s Research UKAvanti Polar Lipids, Inc.*Bethyl Laboratories, Inc.*Canadian HIV Vaccine Initiative Research & Development AllianceCEDARLANE*Cellular Dynamics International*Chroma Technology Corporation*Coy Laboratory Products Inc.*Crohn’s & Colitis Foundation of AmericaDevelopment, The Company of Biologists LtdeLife*

Janssen R&D: Pharmaceutical Companies of Johnson & Johnson*Monsanto Company*Sanofi US*

Educational grant from Lilly Merck & Co., Inc. Novo Nordisk A/SPfizer Inc.Regeneron Pharmaceuticals, Inc. RocheTakeda Pharmaceutical Company Limited

Constellation Pharmaceuticals Curemark LLC Genentech, Inc. Gilead Sciences, Inc. GlaxoSmithKline H3 Biomedicine Inc. Infinity Pharmaceuticals, Inc. InterMune, Inc. Isis Pharmaceuticals, Inc. Janssen R&D: Pharmaceutical Companies of Johnson & Johnson Life Technologies Corporation Educational grant from Lilly

Landes Bioscience*March of Dimes Foundation Grant No. 4-FY14-469

The Ellison Medical Foundation Evotec* Exiqon A/S* FEI Company* Genkyotex SA Glenn Foundation for Medical Research HypOxygen* Integrated DNA Technologies* Inventiva* Ruskinn Technology Ltd, a division of the Baker Company, Inc.* Seahorse Bioscience, Inc.* Zymo Research Corporation*

Mucosal Immunology Studies Team (MIST), in memory of Dr. Leo LeFrancois Myriad-RBM New England Biolabs, Inc.* Opsona Therapeutics Ltd* Peregrine Pharmaceuticals Inc.* Promedior, Inc. Promega Corporation Proteostasis Therapeutics, Inc.* R&D Systems, Inc.* Research Diets, Inc.* Syngenta Biotechnology, Inc.* Takeda California* The Rockefeller University Press – The Journal of Experimental Medicine*

US GOVERNMENT GRANTS

Keystone Symposia appreciates grants to support various 2014 meetings received from the following government agencies:

National Institutes of Health (NIH):National Center for Advancing Translational Science (NCATS)National Cancer Institute (NCI)National Heart, Lung, and Blood Institute (NHLBI)National Institute on Aging (NIA)National Institute of Allergy and Infectious Diseases (NIAID)National Instiutte of Arthritis and Muscoskeletal and Skin Diseases (NIAMS)National Institute of Biomedical Imaging and Engineering (NIBIB)Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)National Institute of Dental and Cranofacial Research (NIDCR)National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)National Institute of General Medical Sciences (NIGMS)National Institute of Neurological Disorders and Stroke (NINDS)

National Science Foundation (NSF)

10

PARTNERS, PATRONS, DONORS AND CONTRIBUTORS (CONTINUED)

DONORS($2,500–$4,999)

Agilent Technologies*ALPCO Diagnostics* inBioSpherix, Ltd.*BioVentures, Inc.*Bruker AXS, Inc.Bruker Corporation*Cayman Chemical Company*Cubist Pharmaceuticals, Inc.*Cytokinetics, Inc.*Dow AgroSciences*Escher Fund for AutismEssential Pharmaceuticals*ISOTEC, a member of the Sigma-Aldrich Group*KWS SAAT AG*MitoKyne*

CONTRIBUTORS(up to $2,499)

Arraystar Inc.*Journal of Lipid ResearchNew Era Enterprises, Inc.

Donor Support

Orphagen PharmaceuticalsRaNA Therapeutics

DIVERSITY PROGRAM SUPPORT

Keystone Symposia is grateful to the following 2014 supporters of its Diversity in Life Science Programs.

Alfred P. Sloan FoundationBiogen Idec

National Institute of General Medical Sciences (NIGMS), NIH, Minority Access to Research Careers (MARC)

11

These generous alumni of previous meetings and others with a passion for ensuring a future of scientific discovery that benefits humankind have made gifts in the fiscal year ending June 30, 2014 to support the Keystone Symposia Future of Science Fund. Through their generosity, we are able to provide scholarships and travel awards to the next generation of biomedical and life scientists, whose education and careers are enhanced by the opportunity to attend meetings and interact with the world’s leading senior scientists.

PRESIDENT’S CIRCLE ($10,000+)The Elkes Foundation

FOUNDERS’ SOCIETY ($5,000–$9,999)Vishva DixitA.J. MillerDavid and Marcy Woodland

KEYSTONE CHAMPIONS ($1,000–$4,999)Jim and Sue AikenEdward A. DennisSydney E. Frank FoundationIn Honor of Jeffrey M. Gimble, M.D., Ph.D.Margaret Liu and Robert JohnsonWalter Moos and Susan MillerMarco and Sofia PocaiTerry J. OpgenorthJo VineyIan A. WilsonJuleen R. Zierath

KEYSTONE BENEFACTORS ($500–$999)Jon AsterCintia S. De PaivaPhyllis McNeilToshio SudaKazuo TsubotaBei ZhangAnonymous (1)

KEYSTONE PATRONS ($100–$499)E. Dale AbelSaleh Al-FarrajStephen AndersonClaus AnderssonWolfgang BergmeierBonnie B. BlombergAlberto BosqueRalph A. BradshawCherié L. ButtsFabio CiceriBruce CronsteinHeidi Daetwyler*Pamela S. Daugherty*Lee EllisHarald EsterbauerJohn FoleyJanusz Franco-Barraza*Opher GileadiHugo GramajoElizabeth (Lisa) Henske*Linda HrycajShie-Liang HsiehThe Humke FamilyKyoko Imanaka-Yoshida

Elizabeth Jaffee Marcus Jones Prem Kalra Shohei Koide Masayasu Kojima Huachun Larue Patricia LiWang Martin McCarter Heber Nielsen Tamas Ordog Vito Palombella Eric and Victoria Parker Alexander Pertsemlidis Patrick J Pollard Marc Prentki Suzie Scales Dr. Anish Sen Majumdar Yan Shi with matching gift from Bristol-Myers Squibb Company Employee Giving Program Naglaa Shoukry Simon Spivack Peter Strop Malu Tansey James W. Thomas James Trager Toshihiro Umehara Bruno Vaslin Trudi Veldman Xiaoli Wang Sally Wenzel-Morganroth Judith White Aprilianto Eddy Wiria Tai June Yoo Anonymous (6) KEYSTONE CONTRIBUTORS ($10–$99) Joanne Adamkewicz Raid Albaradie Stephen Anderson Paulo R.Z. Antas Rafael Arrojo e Drigo Jan Bakker Jimena Baleriola Lea Beaulieu Marie-Jose Bijlmakers Jonas Blomberg James Bone Alexandra Cantley Wei Chen Ana Cheong Valerio Chiurchiù Sang Nae Cho Alan Clarke Carl Classen

Rhea & Clark Coler Claudio Cortes Peter Crawford Kenneth Cremer Maria Curotto de Lafaille Poonamjot Deol Alexandre Deshiere Larry Dishaw Mayra Domínguez Pérez Wenjuan Dong Jonas Dutra Albarnaz Christoph Ellebrecht Alvaro Elorza Nora Engel Lluis Espinosa Blay Becket Feierbach Richard Fisher Flavio Fontana Barbara Fox Nicole Frahm Dinorah Friedmann-Morvinski Katsunori Fujii Miho Funaki Zhihuan Gao Jean-Charles J. B. Grivel Carlos Guerrero-Bosagna Volker H. Haase Yuan-Ping Han Thomas Hanke Anja Harmeier Thomas J. Hawke Julia Heinrich David A. Horwitz Hongzhen Hu Huey-Jing Huang Stephane Illiano Mi-Hyeon Jang Jae-Han Jeon Shengfang Jin Tim Johnson Kyuho Kang Ana Katusic Bojanac Marcus Kaul Dineo Khabele Thomas Kietzmann Soichi Kojima Ryszard Kole Suneil Koliwad Robert A. Koza Eun Kyung Kwon Mark Lang Barbara Laughon Dan Lazar Dae Ho Lee Eun Soo Lee

Keystone Symposia Future of Science Fund Donors

National Institute of General Medical Sciences (NIGMS), NIH, Minority Access to Research Careers (MARC)

12

Seung-Pyo Lee Wang Lee Jeff Leips Shuhai Lin Pam Lincez Haiying Liu Thomas Alexander Lutz Mahin D. Maines Shota Maki Kathryn Malecek Humberto Martinez Montoya Paolo Martini David Masopust & Vaiva Vezys Jan Mauer Kevin McLure Jomkhwan Meerak Lisethe Meijer Brenda Mengeling Manzoor Mir Naoyuki Miura Shelley Miyamoto Annie Moisan Masahiro Morita Tammy Morrish Herbert Morse, III Zissimos Mourelatos Rita Mozes-Koch Savannah Mwesigwa Asuka Nakata Yayoi Natsume-Kitatani Leonid Nikitenko Steven Nye Takashi Obata

Ulf Orom Kwaku Owusu-Darko Olga Pakhomova Maria V. Papadopoulou Hyunsung Park Sun Ah Park Ruth Perez Kevin Peters Jean-Francois Peyron Sundiep Phanse Chris Phillips Francesco Piccolo Oren Pleniceanu Linsey Porter Bronislaw Pytowski Minoo Rassoulzadegan David Ratner Vincent Raussens Anuradha Ray Prabir Ray Guilherme Rocha Laurent Sabbagh Junichi Sadoshima Leonardo Sahelijo Karissa Sanbonmatsu Uma Sankar Demba Sarr Yoshihiko Satoh Ilya Scheglov Takao Seki Andrew Shin Nadisha Silva Venkateswara Rao Simhadri

Catharine L. Smith Katsura Soma Wenxia Song Lydia Stefanescu Francesca Storici Gary Strichartz Akira Suzuki Tetsuya Tanaka Jamshid Tanha Elizabeth Tarling Malav Trivedi Jennifer Tsai Eleni Tseliou Ivan Uray Thomas Vallim Keith Van Haren Han Verhagen Arthur Verhoeven Simon Vidal Arnaud Vincent Carston Wagner Doris Wilflingseder John Worthington Linda Wu Ming-Sian Wu Xiaojian Yao James Yarger Yibin Wang Sara Zanivan Lan Zhou Xinjun Cindy Zhu Anonymous (3)

Keystone Symposia Future of Science Fund Donors

The Keystone SocietyCharter Members

Jim and Sue AikenChristopher Atwood

Anish and Sushmita Sen MajumdarJo Viney

David and Marcy Woodland

In 2012, Keystone Symposia formed a new society to recognize meeting alumni and friends who make estate contributions (e.g., simple bequests, planned gifts, other estate provisions) of any amount or percentage of estate to the Keystone Symposia Future of Science Fund. Keystone Society members will be recognized in perpetuity on all Keystone Symposia acknowledgement platforms, including websites, conference abstract books and annual reports.

Those joining The Keystone Society before June 30, 2014 are recognized in perpetuity as Charter Members. Donors always have the option of making their gifts anonymously.

*Indicates a donation on a recurring monthly basis.

13

BENEFACTORS ($50,000+)

American Association for the Advancement of Science (AAAS)BioMed Central LtdCell PressNature Publishing GroupThe Scientist

SPONSORS ($25,000–$49,999)

EMBO (European Molecular Biology Organization)Mary Ann Liebert, Inc. PublishersPLOSS. Karger A.G.The LancetThe Rockefeller University Press – The Journal of Cell Biology

PARTNERS ($10,000–$24,999)

FOCIS (Federation of Clinical Immunology Societies)Landes BioscienceMalaria NexusThe Company of Biologists LtdThe Rockefeller University Press – The Journal of Experimental Medicine

PATRONS ($5,000–$9,999)

British Society for ImmunologyFEBS Letters (Elsevier)The Journal of Clinical Investigation

DONORS ($2,500–$4,999)

Big Data journal (Mary Ann Liebert, Inc. Publishers)Euromit 2014Biochemical Society / Biochemical JournalSAGE: Cephalalgia, published by SAGE on behalf of the International Headache Society

CONTRIBUTORS (up to $2,499)

American Society of Plant BiologistsEntomological Society of AmericaHypoxia journal – Dove Medical PressInternational Chemical Biology SocietyInternational Society for Stem Cell Research (ISSCR)The Beatson Institute for Cancer ResearchThe Protein Society

The following publishers, societies and other organizations provided in-kind marketing and advertising support that helped publicize the 2014 Keystone Symposia meeting series.

The following companies generously agreed to forego reimbursements for speaker travel and lodging expenses in order to support 2014 Keystone Symposia meeting programs.

Alexion Pharmaceuticals, Inc.Alnylam Pharmaceuticals, Inc.Amgen Inc.Biogen IdecBristol-Myers Squibb CompanyCellzome – a GSK CompanyConcert Pharmaceuticals, Inc.Dynavax Technologies CorporationEli Lilly and CompanyEMBO Young Investigator ProgrammeGenentech, Inc.GlaxoSmithKlineHeptares Therapeutics LtdHoffmann-La Roche Inc.Illumina, Inc.

MedImmuneMerckNovartis Institutes for BioMedical ResearchNovartis Pharma AGNovartis Vaccines and DiagnosticsPfizer Inc.Pfizer OncologyPromedior, Inc.RaNA TherapeuticsRegeneron Pharmaceuticals, Inc.Regulus Therapeutics Inc.Roche Diagnostics GmbHSangamo BioSciences, Inc.Transgene SA

MARKETING/ADVERTISING IN-KIND DONORS

SPEAKER GIFT-IN-KIND DONORS

Keystone Symposia In-Kind Donors

From left: Keystone Symposia Fellows receive their diplomas at the June 2014 Keystone Symposia Scientific Advisory Board meeting; four expert HIV/AIDS researchers discuss “Strategies for an Endgame” in Keystone Symposia’s first virtual webcast event; Jim Aiken chats with staff at his retirement party after 11 years as CEO of Keystone Symposia.

Juleen R. Zierath, Ph.D.Chair of the Board, Keystone SymposiaProfessor, Molecular Medicine and Surgery, Karolinska Institutet

Gary J. Nabel, M.D., Ph.D. Secretary of the Board Chair, Scientific Advisory Board Chief Scientific Officer, Research and Development Sanofi

Terry J. Opgenorth, Ph.D.Treasurer of the BoardChair, Finance Committee, Keystone SymposiaChief Operating Officer, NeoTREXCSU Ventures, Inc., Colorado State University

Jane L. Peterson, Ph.D.President and Chief Executive OfficerKeystone Symposia on Molecular and Cellular Biology

David L. Woodland, Ph.D.Chief Scientific OfficerKeystone Symposia on Molecular and Cellular Biology

E. Dale Abel, M.D., Ph.D. Director, F.O.E. Diabetes Research Center Professor of Medicine and Biochemistry University of Iowa Carver College of Medicine

Vishva M. Dixit, M.D. Vice President, Early Discovery Research and Physiological Chemistry Genentech, Inc.

Beverly M. Emerson, Ph.D.Chair, Personnel Committee, Keystone SymposiaProfessor, Regulatory Biology LaboratoryThe Salk Institute

Peter M. Finan, Ph.D.Chair, Audit Committee, Keystone SymposiaDirector, Pathways Biology, Developmental and Molecular PathwaysNovartis Institutes for BioMedical Research

Heidi E. Hamm, Ph.D.Chair, Globalization Committee, Keystone SymposiaProfessor and Chair, Department of PharmacologyVanderbilt University School of Medicine

Walter Moos, Ph.D.Vice PresidentBiosciences DivisionSRI International

Alan Sher, Ph.D.Chair, Nominating Committee, Keystone SymposiaBethesda, Maryland

Ian A. Wilson, Ph.D., Sc.D., FRSProfessor, Department of Molecular Biology and The Skaggs Institute for Chemical BiologyThe Scripps Research Institute

Tadataka Yamada, M.D. Board Member, Executive Vice President and Chief Medical and Scientific Officer Takeda PharmaceuticalsBei B. Zhang, Ph.D. General Manager, Lilly China Research and Development Co. LTD (LCRDC) Vice President, Lilly Research Laboratories, Eli Lilly and Company

EMERITUS BOARD MEMBERS

Ralph A. Bradshaw, Ph.D.Professor Emeritus, Physiology and BiophysicsCollege of Medicine, University of California, IrvineProfessor in Pharmaceutical Chemistry and Deputy Director of Mass Spectrometry Facility, University of California, San Francisco

Robert W. CraigPresident Emeritus, The Keystone Center

Edward A. Dennis, Ph.D.Professor, Chemistry, Biochemistry and PharmacologySchool of Medicine, University of California, San Diego

Curtis C. Harris, M.D.Chief, Laboratory of Human CarcinogenesisNCI/National Institutes of Health

Note: All Board and Emeritus Board Members are also members of Keystone Symposia’s Scientific Advisory Board.

Jane L. Peterson, Chief Executive OfficerPamela Daugherty, Chief Financial OfficerDavid Woodland, Chief Scientific OfficerJames Aiken, Leadership Transition ConsultantJeannie Dalrymple, Senior Director, Program Development & ImplementationLinda Hrycaj, Senior Director, Strategic PlanningChristopher Atwood, Director, Development Heidi Daetwyler-Simpson, Director, Meeting ManagementLaina King, Director, Diversity in Life Science ProgramsTanya Muller, Director, Information TechnologyYvonne Psaila, Director, Marketing & CommunicationsMary Jo Roal, Director, Human Resources David Adamson, On-Site Staff RepresentativeCathy Banks, Web Developer/Systems AnalystCarol Bosserman, On-Site Staff RepresentativeMary Brown, On-Site Staff RepresentativeCaroline Brendel, Executive Administrative AssistantDoug Castle, Web Developer/Systems AnalystLinda Cooper, Abstracts AssistantChris Dean, IT Support SpecialistAmanda Deem, Assistant Director of Development

Camille Dubroff, Administrative & Research Assistant, DevelopmentHeather Gerhart, Senior Grant Coordinator/Program AnalystSusan Gunn, Logistics SpecialistMarion Hart, Program Implementation AssistantLindsey Heilmann, Conference CoordinatorJenny Hindorff, Program Implementation AssociateSarah Lavicka, Assistant Director of DevelopmentJeff Lehman, Scholarship CoordinatorPhyllis McNeil, Attendee Services SpecialistAllison Ogdon, Senior Program Development CoordinatorAnnie Page, On-Site Staff RepresentativeGrace Roath, Office ManagerJulie Roll, On-Site Staff RepresentativeDavid Sanchez, Manager, Attendee ServicesBarbara Schmid-Miller, Marketing Assistant Gwyn Schmude, Attendee Services SpecialistDawn Shafer, Accounting ClerkBridget Stacy, Administrative Assistant, Diversity in Life Science Programs Kathy Tavares, Program Implementation SupervisorJohn Tavery, On-Site Staff RepresentativeRebecca Wilkerson, Finance Assistant

14

Board of Directors (as of June 30, 2014)

Staff (as of June 30, 2014)

Walter Moos, Ph.D.Vice PresidentBiosciences DivisionSRI International

Alan Sher, Ph.D.Chair, Nominating Committee, Keystone SymposiaBethesda, Maryland

Ian A. Wilson, Ph.D., Sc.D., FRSProfessor, Department of Molecular Biology and The Skaggs Institute for Chemical BiologyThe Scripps Research Institute

Tadataka Yamada, M.D. Board Member, Executive Vice President and Chief Medical and Scientific Officer Takeda PharmaceuticalsBei B. Zhang, Ph.D. General Manager, Lilly China Research and Development Co. LTD (LCRDC) Vice President, Lilly Research Laboratories, Eli Lilly and Company

EMERITUS BOARD MEMBERS

Ralph A. Bradshaw, Ph.D.Professor Emeritus, Physiology and BiophysicsCollege of Medicine, University of California, IrvineProfessor in Pharmaceutical Chemistry and Deputy Director of Mass Spectrometry Facility, University of California, San Francisco

Robert W. CraigPresident Emeritus, The Keystone Center

Edward A. Dennis, Ph.D.Professor, Chemistry, Biochemistry and PharmacologySchool of Medicine, University of California, San Diego

Curtis C. Harris, M.D.Chief, Laboratory of Human CarcinogenesisNCI/National Institutes of Health

Note: All Board and Emeritus Board Members are also members of Keystone Symposia’s Scientific Advisory Board.

Camille Dubroff, Administrative & Research Assistant, DevelopmentHeather Gerhart, Senior Grant Coordinator/Program AnalystSusan Gunn, Logistics SpecialistMarion Hart, Program Implementation AssistantLindsey Heilmann, Conference CoordinatorJenny Hindorff, Program Implementation AssociateSarah Lavicka, Assistant Director of DevelopmentJeff Lehman, Scholarship CoordinatorPhyllis McNeil, Attendee Services SpecialistAllison Ogdon, Senior Program Development CoordinatorAnnie Page, On-Site Staff RepresentativeGrace Roath, Office ManagerJulie Roll, On-Site Staff RepresentativeDavid Sanchez, Manager, Attendee ServicesBarbara Schmid-Miller, Marketing Assistant Gwyn Schmude, Attendee Services SpecialistDawn Shafer, Accounting ClerkBridget Stacy, Administrative Assistant, Diversity in Life Science Programs Kathy Tavares, Program Implementation SupervisorJohn Tavery, On-Site Staff RepresentativeRebecca Wilkerson, Finance Assistant

Tony Pawson, an investigator at the Lunenfeld-Tanenbaum Research Institute in Toronto, Canada and a past Kyoto Prize winner in 2008, was a valued member of Keystone Symposia’s Board of Directors from 2006 to 2013, when he passed away in August at the age of 60. A frequent Keystone Symposia attendee, speaker and organizer since 1978, Tony was instrumental in developing the organization’s long series of signal transduction meetings. He was one of the distinguished speakers at the memorable 2000 Keystone Symposia Millennium conference organized by David Baltimore. Most recently, he co-organized Keystone Symposia’s 40th-anniversary commemoration conference in January 2011 on “The Evolution of Protein Phosphorylation.” In the words of one attendee of that meeting, “The best meetings I’ve ever attended are those run by Tony Pawson and Tony Hunter.”

According to Tony Hunter, “Tony was a giant in the field of signal transduction, who established principles of protein-protein interactions that have profoundly influenced our understanding of signal transduction. His enduring legacy will be the discovery that the Src homology 2 (SH2) domain of one protein can selectively interact with a tyrosine residue in a second protein, once it is phosphorylated in response to an upstream signal. This type of inducible protein-protein interaction can link intracellular signals generated in response to various upstream stimuli to downstream signaling events. This insight was the basis for Tony’s enormously influential idea that eukaryotic signaling systems involve modular protein interaction domains that are used in combination to propagate signals throughout the cell.”

Juleen Zierath speaks for all on the Board when remembering Tony as a “genuinely kind and humble man whose passion for science was matched by his sincere concern for others.”

The January 2015 Keystone Symposia meeting on “The Biological Code of Cell SIgnaling,” organized by Tony Hunter and Rune LInding, is dedicated to the memory of Tony Pawson and his many remarkable achievements.

Tony is missed by everyone on the Board and Staff of Keystone Symposia, as he is by all in the scientific community.

Remembering Board Member Dr. Tony Pawson

(1952–2013)

James W. Aiken, Ph.D. Leadership Transition Consultant Keystone Symposia on Molecular and Cellular Biology

James E. Audia, Ph.D. Chief Scientific Officer Constellation Pharmaceuticals

Jacques F. Banchereau, Ph.D. Professor and Director of Immunological Sciences The Jackson Laboratory for Genomic Medicine

J. Carl Barrett, Ph.D. Vice President, Translational Science Oncology Innovative Medicines AstraZeneca

Dominic P. Behan, Ph.D., D.Sc. Executive Vice President and Chief Scientific Officer Arena Pharmaceuticals, Inc.

Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer Dynavax Technologies

Rodrigo Corrêa-Oliveira, Ph.D. Senior Researcher Laboratório de Imunologia Celular e Molecular FIOCRUZ Minas

Russell A. DeBose-Boyd, Ph.D. Professor Molecular Genetics University of Texas Southwestern Medical Center

Martin P. Edwards, Ph.D. Vice President, Cancer Chemistry Pfizer La Jolla

Curt R. Freed, M.D. Professor and Head Division of Clinical Pharmacology and Toxicology University of Colorado, Denver

Adolfo García-Sastre, Ph.D. Professor, Microbiology Mount Sinai School of Medicine

Tariq Ghayur, Ph.D. Senior Research Fellow, Biologics AbbVie

Margaret A. Goodell, Ph.D. Professor, Pediatrics, Hematology/Oncology Director, STaR Center Center for Cell and Gene Therapy Baylor College of Medicine

Philip D. Gregory, Ph.D. Chief Scientific Officer Research Sangamo BioSciences, Inc

Diane E. Griffin, M.D., Ph.D. Professor and Chair Molecular Microbiology and Immunology Johns Hopkins Bloomberg School of Public Health

Austin Gurney, Ph.D. Senior Vice President, Molecular & Cellular Biology OncoMed Pharmaceuticals, Inc.

Jacqueline E. Heard, Ph.D. Venture Capital Principal Global Strategy and R&D Investments Monsanto Company

Sharath S. Hegde, Ph.D.Vice President, Department of PharmacologyTheravance, Inc.

Kim A. Heidenreich, Ph.D. Professor, Department of Pharmacology University of Colorado Denver (UCHSC)

Matthew F. Heil, Ph.D. Chief Scientific Officer Research and Development Curemark LLC

Christopher L. Karp, M.D. Deputy Director, Vaccines and Host-Pathogen Biology Global Health Discovery and Translational Sciences Bill & Melinda Gates Foundation

Laura L. Kiessling, Ph.D. Hilldale Professor of Chemistry Laurens Anderson Professor of Biochemistry Department of Chemistry and Biochemistry University of Wisconsin–Madison

Jacqueline Kirchner, Ph.D. Executive Director, Research Inflammation Amgen

Karla Kirkegaard, Ph.D. Professor, Microbiology and Immunology Stanford University School of Medicine

Martin Kussmann, Ph.D. Head of Proteomics & Metabonomics Core Nestlé Institute of Health Sciences

Jan E. Leach, Ph.D. University Distinguished Professor Bioagricultural Sciences Colorado State University

Hyam I. Levitsky, M.D. Head, Human Immunology Roche Glycart AG

Karolin Luger, Ph.D. Professor and HHMI Investigator Department of Molecular Biology and Biochemistry Colorado State University

Paolo G.V. Martini, Ph.D. Senior Director Drug Discovery and Translational Research Shire Human Genetic Therapies

Lamine Mbow, Ph.D. Director, Immunology and Inflammation Boehringer Ingelheim

Elizabeth M. McNally, M.D., Ph.D. Professor Department of Medicine and Human Genetics University of Chicago

Juanita L. Merchant, M.D., Ph.D. Professor, Internal Medicine and Molecular and Integrative Physiology University of Michigan

Tara Mirzadegan, Ph.D. Senior Director, CREATe Janssen R&D: Pharmaceutical Companies of Johnson & Johnson

Peter Mueller, Ph.D. Executive Vice President, Global Research and Development and Chief Scientific Officer Vertex Pharmaceuticals Incorporated

Dominik Mumberg, Ph.D. Director, Cell Cycle and Survival Signaling Research Global Drug Discovery Bayer HealthCare

Steven G. Nadler, Ph.D. Group Director Translational Research Immuno-Sciences Biology Drug Discovery Bristol-Myers Squibb Company

Anne O’Garra, Ph.D., FRS, FMedSci Head, Division of Immunoregulation MRC National Institute for Medical Research

Vito J. Palombella, Ph.D. Chief Scientific Officer Infinity Pharmaceuticals, Inc.

Eric M. Parker, Ph.D. Senior Director and Neuroscience Site Lead Neuroscience and Ophthalmology Merck Research Laboratories

Mark Powers, Ph.D. Senior Director, Research & Development Primary and Stem Cell Systems Life Technologies Corporation

Ronald T. Raines, Ph.D. Professor Departments of Biochemistry and Chemistry University of Wisconsin–Madison

Fred J. Ramsdell, Ph.D. Director, Discovery Immunology Novo Nordisk

Cristina M. Rondinone, Ph.D. Vice President, Research and Development Head, Cardiovascular and Metabolic Diseases MedImmune

Nadia A. Rosenthal, Ph.D. Director, Australian Regenerative Medicine Institute Scientific Head, EMBL Australia Monash University

Andrej Sali, Ph.D. Professor, Bioengineering and Therapeutic Sciences University of California, San Francisco

Alejandro Sánchez-Alvarado, Ph.D. Investigator HHMI/Stowers Institute for Medical Research

Stephen J. Simpson, Ph.D. Director of Research Programmes & Information Research, Education and Information Arthritis Research UK

Frank J. Slack, Ph.D. Professor Molecular, Cellular and Developmental Biology Yale University

Linda Slanec Higgins, Ph.D. Vice President, Biology Gilead Sciences, Inc.

Eric E. Swayze, Ph.D. Vice President, Medicinal Chemistry ISIS Pharmaceuticals

Doris A. Taylor, Ph.D. Director, Regenerative Medicine Research Texas Heart Institute

Mathias Uhlén, Ph.D. Professor School of Biotechnology KTH Royal Institute of Technology

Joanne L. Viney, Ph.D. Vice President, Immunology Research Biogen Idec

Michael J.O. Wakelam, Ph.D. Institute Director The Babraham Institute

Andrew Ward, Ph.D. Assistant Professor, Molecular Biology The Scripps Research Institute

Markus Warmuth, M.D. President and Chief Executive Officer H3 Biomedicine Inc.

Kenneth F. Wertman, Ph.D. Scientific Director, Tucson Associate Vice President, Discovery Research Chemical Analytical Sciences Sanofi US

Peter J. Worland, Ph.D. Vice President, Integrative Research Development Executive Research Celgene Corporation

Scientific Advisory Board (as of June 30, 2014)

The 2014 Meeting Season (October 2013 – June 2014)

Advancing Vaccines in the Genomics Era (T1) Oct 31–Nov 4, 2013 | Windsor Barra Hotel | Rio de Janeiro | Brazil

Sensing and Signaling of Hypoxia: Interfaces with Biology and Medicine (A1) Jan 7–12, 2014 | Beaver Run Resort | Breckenridge, Colorado | USA

The Ubiquitin System: From Basic Science to Drug Discovery (A2) Jan 7–12, 2014 | Big Sky Resort | Big Sky, Montana | USA

Nuclear Receptors: Biological Networks, Genome Dynamics and Disease (A3) Jan 10–15, 2014 | Sagebrush Inn and Conference Center | Taos, New Mexico | USA

Tissue-Resident Memory T Cells (A4) Jan 12–16, 2014 | Snowbird Resort | Snowbird, Utah | USA

Aging – Pushing the Limits of Cellular Quality Control (A5) Jan 12–17, 2014 | Sheraton Steamboat Resort | Steamboat Springs, Colorado | USA

Challenges and Opportunities in Diabetes Research and Treatment (J1) joint with Obesity: A Multisystems Perspective (J2) Jan 12–17, 2014 | Fairmont Hotel Vancouver | Vancouver, British Columbia | Canada

Emerging Cytokine Networks (J3) joint with Inflammatory Diseases: Recent Advances in Basic and Translational Research and Therapeutic Treatments (J4) Jan 17–22, 2014 | Fairmont Hotel Vancouver | Vancouver, British Columbia | Canada

Pathogenesis of Respiratory Viruses (J5) joint with Innate Immunity to Viral Infections (J6) Jan 19–24, 2014 | Keystone Resort | Keystone, Colorado | USA

New Frontiers in the Discovery and Treatment of Thrombosis (A6) Jan 26–30, 2014 | Keystone Resort | Keystone, Colorado | USA

Mechanisms and Consequences of Invertebrate-Microbe Interactions (A7) Jan 26–30, 2014 | Granlibakken Resort | Tahoe City, California | USA

Growth and Wasting in Heart and Skeletal Muscle (A8) Jan 26–31, 2014 | Eldorado Hotel & Spa | Santa Fe, New Mexico | USA

RNA Silencing (A9) Jan 31–Feb 5, 2014 | Sheraton Seattle Hotel | Seattle, Washington | USA

The Science of Malaria Eradication (F1) Feb 2–7, 2014 | Fiesta Americana | Merida, Yucatan | Mexico

Developmental Pathways and Cancer: Wnt, Notch and Hedgehog (J7) joint with Stem Cells and Cancer (J8) Feb 2–7, 2014 | Fairmont Banff Springs | Banff, Alberta | Canada

Cancer Epigenetics (Q1) joint with Transcriptional Regulation (Q2) Feb 4–9, 2014 | Santa Fe Community Convention Center | Santa Fe, New Mexico | USA

Plant Signaling: Dynamic Properties (B1) Feb 5–10, 2014 | Beaver Run Resort | Breckenridge, Colorado | USA

Molecular Cell Biology of Macrophages in Human Diseases (B2) Feb 9–14, 2014 | Hilton Santa Fe Historic Plaza Hotel | Santa Fe, New Mexico | USA

Prophylactic and Therapeutic Antibodies (Q3) joint with Biology of B Cell Responses (Q4) Feb 9–14, 2014 | Keystone Resort | Keystone, Colorado | USA

Omics Meets Cell Biology: Applications to Human Health and Disease (B3) Feb 18–23, 2014 | Sagebrush Inn and Conference Center | Taos, New Mexico | USA

Mitochondrial Dynamics and Physiology (Q5) joint with The Chemistry and Biology of Cell Death (Q6) Feb 18–23, 2014 | Santa Fe Community Convention Center | Santa Fe, New Mexico | USA

The NF-κB System in Health and Disease (B4) Feb 23–28, 2014 | Keystone Resort | Keystone, Colorado | USA

Long Noncoding RNAs: Marching toward Mechanism (B5) Feb 27–Mar 4, 2014 | Eldorado Hotel & Spa | Santa Fe, New Mexico | USA

Cilia, Development and Human Disease (C1) Mar 2–7, 2014 | Granlibakken Resort | Tahoe City, California | USA

Parkinson’s Disease: Genetics, Mechanisms and Therapeutics (Q7) joint with Alzheimer’s Disease – From Fundamental Insights to Light at the End of the Translational Tunnel (Q8) Mar 2–7, 2014 | Keystone Resort | Keystone, Colorado | USA

Mobile Genetic Elements and Genome Evolution (C2) Mar 9–14, 2014 | Hilton Santa Fe Historic Plaza Hotel | Santa Fe, New Mexico | USA

Inflammation, Infection and Cancer (X1) joint with Immune Evolution in Cancer (X2) Mar 9–14, 2014 | Fairmont Chateau Whistler | Whistler, British Columbia | Canada

HIV Vaccines: Adaptive Immunity and Beyond (X3) joint with HIV Pathogenesis–Virus vs. Host (X4) Mar 9–14, 2014 | Fairmont Banff Springs | Banff, Alberta | Canada

Metabolism and Angiogenesis (X5) joint with Tumor Metabolism (X6) Mar 16–21, 2014 | Whistler Conference Centre | Whistler, British Columbia | Canada

Lipid Pathways in Biology and Disease (C3) Mar 19–24, 2014 | Royal Dublin Society | Dublin | Ireland

Big Data in Biology (F2) Mar 23–25, 2014 | Fairmont San Francisco | San Francisco, California | USA

Fibrosis: From Bench to Bedside (C4) Mar 23–28, 2014 | Keystone Resort | Keystone, Colorado | USA

Chromatin Mechanisms and Cell Physiology (C5) Mar 23–28, 2014 | Oberstdorf Haus | Oberstdorf | Germany

Complications of Diabetes (X7) joint with Innate Immunity, Metabolism and Vascular Injury (X8) Mar 23–28, 2014 | Whistler Conference Centre | Whistler, British Columbia | Canada

The Ins and Outs of Viral Infection: Entry, Assembly, Exit and Spread (C6) Mar 30–Apr 4, 2014 | Beaver Run Resort | Breckenridge, Colorado | USA

Novel Therapeutic Approaches to Tuberculosis (C7) Mar 30–Apr 4, 2014 | Keystone Resort | Keystone, Colorado | USA

G Protein-Coupled Receptors: Structural Dynamics and Functional Implications (Z1) joint with Frontiers of Structural Biology (Z2) Mar 30–Apr 4, 2014 | Snowbird Resort | Snowbird, Utah | USA

Exploiting and Understanding Chemical Biotransformations in the Human Microbiome (D1) Apr 1–6, 2014 | Big Sky Resort | Big Sky, Montana | USA

Epigenetic Programming and Inheritance (D2) Apr 6–10, 2014 | Boston Park Plaza | Boston, Massachusetts | USA

Emerging Concepts and Targets in Islet Biology (D3) Apr 6–11, 2014 | Keystone Resort | Keystone, Colorado | USA

Engineering Cell Fate and Function (Z3) joint with Stem Cells and Reprogramming (Z4) Apr 6–11, 2014 | Resort at Squaw Creek | Olympic Valley, California | USA

Adult Neurogenesis (E1) May 12–17, 2014 | Clarion Hotel Sign | Stockholm | Sweden

Autophagy: Fundamentals to Disease (E2) May 23–28, 2014 | Hyatt Regency Austin | Austin, Texas | USA

The Brain: Adaptation and Maladaptation in Chronic Pain (E3) Jun 15–20, 2014 | Keystone Resort | Keystone, Colorado | USA

background photo: Oberstdorf, Germany, new location for Keystone Symposia and site of the 2014

“Chromatin Mechanisms and Cell Physiology” conference

PO Box 1630 | 160 US Highway 6, Suite 200Silverthorne, Colorado 80498 | USA

1.970.262.1230 | 1.800.253.0685 www.keystonesymposia.org